aTYR PHARMA INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
aTYR PHARMA INC (ATYR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.15M, a 12.26% decline year-over-year.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.31M, a 10.95% increase year-over-year.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.31M, a 73.80% increase year-over-year.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.30M, a 79.50% increase year-over-year.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.00M, a 67.18% increase from fiscal 2024.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.99M, a 14.96% increase from fiscal 2023.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.60M, a 20.71% increase from fiscal 2022.
- aTYR PHARMA INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.15M, a 33.46% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.15M 10-Q · filed 2026-08-07 | $2.45M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $1.31M 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $5.00M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.31M 10-Q · filed 2025-11-06 | $2.61M derived: sum of 2 quarters · filed 2026-08-07 | $3.79M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-06-30 | $1.30M 10-Q · filed 2026-08-07 | $2.48M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $1.18M 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $2.99M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $752.00K 10-Q · filed 2025-11-06 | $1.48M derived: sum of 2 quarters · filed 2025-11-06 | $2.22M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $727.00K 10-Q · filed 2025-11-06 | $1.47M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $740.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $2.60M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $664.00K 10-Q · filed 2024-11-07 | $1.32M derived: sum of 2 quarters · filed 2024-11-07 | $1.94M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $658.00K 10-Q · filed 2024-11-07 | $1.28M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $619.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $2.15M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $615.00K 10-Q · filed 2023-11-09 | $1.13M derived: sum of 2 quarters · filed 2023-11-09 | $1.55M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $517.00K 10-Q · filed 2023-11-09 | $934.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $417.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $1.61M 10-K · filed 2024-03-14 | |||
| 2021-09-30 | $442.00K 10-Q · filed 2022-11-14 | $840.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.20M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $398.00K 10-Q · filed 2022-11-14 | $758.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $360.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $1.47M 10-K · filed 2023-03-14 | |||
| 2020-09-30 | $324.00K 10-Q · filed 2021-11-12 | $702.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.13M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $378.00K 10-Q · filed 2021-11-12 | $801.00K derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $423.00K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $1.78M 10-K · filed 2022-03-15 | |||
| 2019-09-30 | $278.00K 10-Q · filed 2020-11-13 | $787.00K derived: sum of 2 quarters · filed 2020-11-13 | $1.36M derived: sum of 3 quarters · filed 2020-11-13 | |
| 2019-06-30 | $509.00K 10-Q · filed 2020-11-13 | $1.08M derived: sum of 2 quarters · filed 2020-11-13 | ||
| 2019-03-31 | $571.00K 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $3.43M 10-K · filed 2021-03-24 | |||
| 2018-09-30 | $690.00K 10-Q · filed 2019-11-14 | $1.90M derived: sum of 2 quarters · filed 2019-11-14 | $2.83M derived: sum of 3 quarters · filed 2019-11-14 | |
| 2018-06-30 | $1.21M 10-Q · filed 2019-11-14 | $2.14M derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2018-03-31 | $928.00K 10-Q · filed 2019-11-14 | |||
| 2017-12-31 | $6.78M 10-K · filed 2020-03-26 | |||
| 2016-12-31 | $5.03M 10-K · filed 2019-03-26 | |||
| 2015-12-31 | $4.86M 10-K · filed 2018-03-20 | |||
| 2014-12-31 | $1.79M 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $155.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |